UroGen Pharma Ltd. (NASDAQ: URGN) closed Q3 2025 with $127.4 million in cash, reporting strong demand growth and increased revenue. The company anticipates smoother processes with the new billing code in 2026, despite potential administrative delays. UroGen’s net loss widened in Q3, driven by rising R&D costs. The company focuses on specialty cancer treatments and minimally invasive therapies. While URGN shows potential as an investment, other AI stocks may offer greater upside. For more insights on AI stocks and investment opportunities, consider exploring the best short-term AI stock options.

Read more at Yahoo Finance: UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs